Open AccessHematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia - SBTMO/SOPOBE 2020 Consensus Guidelines
Author(s) -
Liane Esteves Daudt,
Antônio Vaz de Macedo,
Renata Fittipaldi da Costa Guimarães,
Virginio Fernandes,
Maura R V Ikoma Colturato,
Cláudio Galvão de Castro,
Luciana dos Santos Domingues,
Adriana Seber
Publication year - 2021
Publication title -
journal of bone marrow transplantation and cellular therapy
Language(s) - English
Resource type - Journals
ISSN - 2675-374X
DOI - 10.46765/2675-374x.2021v2n4p141
Subject(s) - medicine , hematopoietic stem cell transplantation , transplantation , conditioning regimen , disease , stem cell , lymphoblastic leukemia , bone marrow transplantation , oncology , bone marrow , leukemia , regimen , immunology , pediatrics , biology , genetics
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative approach to children and adolescents with high-risk acute lymphoblastic leukemia (ALL) at diagnosis or relapsed disease. Nonetheless, despite the graft versus leukemia (GVL) effect, treatment-related morbidity and mortality remains a major challenge. Moreover, the significant heterogeneity of the available data on the selection of patients, type of conditioning regimen, and type of donor hampers any definitive conclusions in the pediatric population. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood ALL to providing evidence-based guidance for the appropriate management of this disease.